Flamingo Therapeutics specialises in RNA-based drug development, with a focus on difficult-to-treat cancers. The company was founded in 2019 based on pioneering work in the field of lncRNAs (long-chain non-coding RNA) with academic partners at VIB, KU Leuven, Ghent University and The University of Michigan.
Flamingo has a strategic partnership with Ionis Pharmaceuticals, a world leader in RNA-targeted antisense oligonucleotide (ASO) therapeutics. Flamingo Therapeutics is headquartered in Belgium with additional operations in the US.
Partners in ambition at Flamingo Therapeutics
PMV is a first-time investor and, together with Kurma Partners, participated in a series A funding round when Flamingo Therapeutics was founded and in a second round in July 2021. The funding will be used to test ASOs against specific target molecules in cancer patients.
- ActivityRNA drug development